Baxter Healthcare Corp.
Deerfield, IL 60015
Share:
Baxter Announces Launch of BAXJECT-® II Needle-Less Transfer Device for ADVATE-®
Latest Convenience Feature for ADVATE Now Available in the United States and European Union DEERFIELD, Ill., Oct. 11 // -- Baxter Healthcare Corporation today announced the availability of BAXJECT II, an innovative needle-less transfer device designed to make the reconstitution and mixing of hemophilia factor therapies easier, faster and safer (as compared to the original BAXJECT and needles)....
Read More »Baxter Announces Launch of BAXJECT-® II Needle-Less Transfer Device for ADVATE-®
Latest Convenience Feature for ADVATE Now Available in the United States and European Union DEERFIELD, Ill., Oct. 11 // -- Baxter Healthcare Corporation today announced the availability of BAXJECT II, an innovative needle-less transfer device designed to make the reconstitution and mixing of hemophilia factor therapies easier, faster and safer (as compared to the original BAXJECT and needles)....
Read More »Baxter and Jerini Advance Program to Develop Non-Intravenous Hemophilia Therapy
DEERFIELD, Ill. and BERLIN, May 18 /PRNewswire-FirstCall/ -- Baxter AG and Jerini AG today announced progress in their collaborative research program to develop a non-intravenous therapy for the treatment of hemophilia. Extensive in vitro and in vivo analyses have identified several synthetic lead molecules with promising pharmacological properties. Using our proprietary technology platform, we...
Read More »Baxter's ADVATE Achieves One Billion Unit Milestone
ADVATE Sales Exceed One Billion Activity Units; New Data Affirms the Therapy's Low Inhibitor Rate DEERFIELD, Ill., Jan. 31 -- Baxter Healthcare Corporation, the leading global hemophilia therapy provider, announced today that accumulated sales of ADVATEÃ-® [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method] have surpassed one billion activity units, in large part because of a...
Read More »